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Mutation of the XNP/ATR-X Gene in a Family with
Severe Mental Retardation, Spastic Paraplegia and
Skewed Pattern of X Inactivation: Demonstration that
the Mutation is Involved in the Inactivation Bias
To the Editor:
A family in which severe mental retardation (MR) is
segregating with spastic paraplegia (SP) has recently
been reported (Martinez et al. 1998). The extended ped-
igree of this family is presented in figure 1. Obligate-
carrier females have a totally skewed pattern of X in-
activation, detected by amplification of the (CAG)n mi-
crosatellite repeat in the androgen-receptor gene and pre-
vious digestion of genomic DNA with the methy-
lation-sensitive restriction endonuclease HpaII, as de-
scribed elsewhere (Martinez et al. 1998). Genetic anal-
ysis in the family has revealed linkage of the morbid
locus to the proximal long arm of the X chromosome,
with a maximum LOD score in Xq13.3. Three genes
involved in X-linked MR (XLMR) have already been
reported in this genomic region. One, encoding oligo-
phrenin-1, is involved in nonsyndromic XLMR (Billuart
et al. 1998) and thus does not seem to be a good can-
didate. The other two are involved in two syndromic
XLMR conditions: Menkes syndrome (MIM 309400)
and alpha-thalassemia with mental retardation (ATR-X
[MIM 301040]) syndrome. The latter is an XLMR con-
dition that associates severe MR, mild alpha-thalasse-
mia, typical facial dysmorphy and a skewed pattern of
X inactivation in carrier females (Gibbons et al. 1995a).
The clinical characteristics of the reported MRSP fam-
ily are close to this description, and thus the presence
of an allelic mutation at the ATR-X locus could be hy-
pothesized. In addition to the already reported clinical
features in the MRSP family, hematologic analysis re-
vealed that 3% of the patients’ erythrocytes showed
HbH inclusions after cresyl-brilliant staining, which re-
inforced the possibility that a mutation in the XNP/ATR-
X gene is present in this family. However, ATR-X syn-
drome has always been reported to be associated with
neonatal hypotonia, which can be severe (Gibbons et al.
1995a). In the case of the family that we studied, affected
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Figure 1 Pedigree of family showing the haplotypes (shown below each analyzed member) of the region linked to the disease. The order
of the markers in the region, with respect to the X inactivation–specific transcript (XIST gene) and the XNP/ATR-X gene, is AR-DXS1275-
XIST-XNP-MNK-DXS1196. Note that III-1 and IV-2 have inherited the disease-linked haplotype (shown in the thicker frames). The percentages
of X inactivation in females are shown (in italics) under the corresponding haplotype (for further details, see text).
patients were affected, from birth, with the opposite
sign, hypertonia. It was thus interesting to look for a
possible new mutation that might lead to a variant of
the disorder.
The gene involved in the ATR-X syndrome was iso-
lated in 1994 (by Gecz et al.) and named “XNP.” It has
since been shown to be mutated in 13 patients with
alpha-thalassemia MR (ATR-X) syndrome (Gibbons et
al. 1995b). Moreover, mutations in this gene have also
been identified in families affected with Juberg-Marsidi
syndrome (MIM 309590) and with MR syndromes
without alpha-thalassemia (Villard et al. 1996a, 1996b,
1996c). More recently, a new mutation has been found,
in Carpenter-Waziri syndrome (Abidi et al. 1999).
The gene is large (probably extending over 300 kb)
and consists of 35 exons. It encodes a putative zinc-finger
helicase (Villard et al. 1997) that is probably involved,
by remodeling the structure of the chromatin, in the
control of gene expression. This assumption is supported
by the finding of an interaction between the XNP protein
and the Ezh2 protein (Cardoso et al. 1998), the human
equivalent of Drosophila enhancer of zeste, a chroma-
tinian protein of the Polycomb group.
To date, 34 different mutations in 50 pedigrees have
been described in the XNP/ATR-X gene, which are lo-
cated either in the region coding for the three zinc-finger
domains of the protein (exons 7 and 8 and the beginning
of exon 9) or in the helicase domain, which extends over
3 kb at the COOH terminus of the putative protein.
We thus decided to search for mutations in this gene
in a patient from the MRSP family. This was per-
formed by systematic sequencing of the gene. We found
one mutation in the gene, changing an arginine from the
conserved helicase domain III into a lysine, R1742K (fig.
2). This mutation perfectly segregates with the disorder
in the family (fig. 3). Moreover, the mutation was absent
from 100 unrelated chromosomes from the same geo-
graphical area as that of the family we studied. We per-
formed reverse-transcription PCR (RT-PCR) on RNA
from lymphocytes of the patients, to check for any pu-
tative effect of the mutation on the mRNA splicing,
which has been previously reported to occur in this gene
(Villard et al. 1996b) but we failed to find any abnormal-
size product (data not shown).
Since this amino acid change (arginine to lysine) is
generally considered to be conservative, we used a local
structure–prediction program (PEPTIDESTRUCTURE,
from the GCG package, which mainly predicts a helices
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Figure 2 Position of mutation in the MRSP family. The top
two lines show the normal XNP protein and nucleotide sequence en-
compassing part of the helicase III domain. The sequences are num-
bered according to GenBank entry U75653. The R1742 residue is
underlined, as is the G5459 nucleotide that is changed into an A and
that causes the replacement of R1742 by K (both the normal and
mutated codons are shaded).
Figure 3 Detection of 5459GrAmutation in the affected branch
of the family. A PCR product obtained by use of two oligonucleotides
flanking the mutation is digested with BseRI and electrophoresed. The
presence of the mutation destroys an internal BseRI site in the am-
plification product. Affected males have a single undigested amplified
allele (one band); carrier-female DNA harboring both a mutated and
a nonmutated allele yields both a digested and a nondigested PCR
product (three bands); and noncarrier females have two digested alleles
(two bands).
and b sheets). This program has predicted a change in
the local structure of the protein (fig. 4), potentially aris-
ing because of steric problems. Arginine 1742 is an
amino acid that cannot be strictly considered to be ev-
olutionarily conserved, but it is present at the same po-
sition in several members of the helicase family of pro-
teins (e.g., in the yeast Rad54 protein).
Very interestingly, in exploring another branch of the
family for the presence of the mutation, we found two
females (individuals III-1 and IV-2 in fig. 1) who share
the disease-associated haplotype, spanning both the
XNP gene and the X-inactivation center, but who lack
the R1742K mutation. We thus can deduce that the mu-
tation arose de novo in the germline of one member of
the founding couple (I-1 or I-2 in fig. 1). Furthermore,
the fact that females in the nonmutated branch of the
family do not exhibit a skewed pattern of X-chromo-
some inactivation demonstrates that the skewing in car-
rier females is directly linked to the presence of the mu-
tation in this gene. This is the first demonstration of a
direct link between a mutation in this gene and the
skewed pattern of X inactivation observed in all carrier
females, and it further supports the pathogenicity of the
R1742K mutation.
We can draw, from these data, two main conclusions.
First, the analysis of this family extends the phenotype
associated with XNP/ATR-X mutations. All patients re-
ported so far were hypotonic (at least in the neonatal
period), which made this trait a major criterion of in-
clusion. In this family, patients are hypertonic and also
present spastic paraplegia. This clinical sign has never
been observed either in classic ATR-X patients or in
related phenotypes such as Juberg-Marsidi syndrome or
Carpenter-Waziri syndrome. Spasticity can develop at
later stages in ATR-X patients, despite neonatal hypo-
tonia, but the patients reported in this study were af-
fected with spasticity from birth. We have no explana-
tion for this, except that no mutation affecting the
helicase III conserved domain has been identified so far.
However, it is difficult to draw conclusions based on the
analysis of a single family.
In contrast, a reexamination of the affected males in
this family shows that, although one affected male does
not exhibit a markedly dysmorphic phenotype, the two
other affected individuals present some facial features in
common with the ones observed in ATR-X syndrome:
everted lower lip with a “carplike” triangular mouth,
hypertelorism, small triangular nose, and broad nasal
root.
The second point regards the skewed pattern of X
inactivation in carrier females. So far, only a close as-
sociation between a bias in X inactivation and a mu-
tation in the gene has been reported, without any direct
proof. In this family, we can observe that the bias in X
inactivation occurs only in females carrying the muta-
tion. Other females, who have received the same chro-
mosome but who are not mutated at the XNP locus, do
not present a skewed pattern of X inactivation, dem-
onstrating that this phenomenon is directly related to a
mutation in the gene. We do not have an explanation
for this phenomenon, but we can postulate two hy-
potheses. First, a mutation in the gene could lead to a
selection, during embryogenesis, that favors the cells ex-
pressing the normal gene product. The second hypoth-
esis is that the gene, which is involved in chromatin-
structure remodeling (Cardoso et al. 1998), could par-
ticipate directly or indirectly in one of the processes of
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Figure 4 Prediction of secondary structures of the normal (con-
tinuous line) and the mutated (dashed line) proteins. CF secondary-
structure prediction according to the Chou-Fasman algorithm; GOR
 the Garnier-Osguthorpe-Robson algorithm. Note the variation for
Turns and b-sheet formation (with CF method) and for Turns and a-
helix formation (with GOR method), in the region surrounding the
R1742K substitution.
X-chromosome inactivation: either spreading or main-
tenance of the inactive state. This would be lethal in
females in whom the mutated allele is expressed, because
functional disomy of the X chromosome is known to be
a lethal condition. Whatever the truth is, it is really strik-
ing to observe that a gene defect that leads to such a
strong counterselection in female carriers and that is not
restricted to certain cell lineages does not impair male
viability. It is, to our knowledge, the first instance in
which such a negative selection against the cells express-
ing an abnormal gene product in females does not imply
a male-lethal condition (discussed in Pegoraro et al.
1997). Although highly skewed X inactivation has been
reported in several other X-linked disorders, it is never
systematically present in the obligate-carrier females
(Orstavik et al. 1998; Plenge et al. 1999).
A final point is that the bias in X inactivation is, to-
gether with severe MR, the only consistent sign in fam-
ilies. This can certainly be important in a first clinical
screening of the patients, before a mutation is sought in
the gene.
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A 22q11.2 Deletion That Excludes UFD1L and
CDC45L in a Patient with Conotruncal and
Craniofacial Defects
To the Editor:
Microdeletions of chromosome 22q11.2 occur with a
high frequency in the general population, with an esti-
mated incidence of 1/3,000–1/4,000 (Burn and Good-
ship 1996). They have been shown to be associated with
the malformation phenotypes of velocardiofacial syn-
drome (VCFS [MIM 192430]), DiGeorge syndrome
(DGS [MIM 188400]), and conotruncal anomaly face
syndrome (CAFS [MIM 217095]) (Emanuel et al.
1999a). Deletions of this region have also been dem-
onstrated in some patients with the autosomal dominant
form of Opitz G/BBB syndrome (MIM 145410)
(McDonald-McGinn et al. 1995). Significant phenotypic
overlap is found among these entities, including cono-
truncal cardiac defects, craniofacial anomalies, learning
disabilities, and cleft palate. The spectrum of clinical
findings shows considerable variability, even within fam-
ilies (McLean et al. 1993).
Although the overwhelming majority (185%) of pa-
tients have deletions of the same ∼3-Mb region (Emanuel
et al. 1999a), several reports have described patients
with atypical, shorter deleted segments nested within the
large typically deleted region (TDR) (Levy et al. 1995;
Kurahashi et al. 1996; O’Donnell et al. 1997; McQuade
et al. 1999). Recently, a small, 20-kb deletion within the
TDR was reported in a patient with a classic VCFS/DGS
phenotype. This smaller deletion disrupts the UFD1L
andCDC45L genes, the products of which (in particular,
UFD1L) have been suggested to play important roles in
craniofacial and cardiac development resulting in the
phenotype (Shaikh et al. 1999; Yamagishi et al. 1999).
However, several of the aforementioned patients (some
of whom have cardiac and craniofacial defects) have
deletions that do not include the region containing these
genes. These observations suggest that additional se-
quences within the TDR affect early craniofacial and
cardiac morphogenesis. Additionally, a patient with fea-
tures of DGS and with a microdeletion that falls outside
the TDR but that does not overlap with any of the
known deletions was recently described (Rauch et al.
1999). This patient had craniofacial abnormalities and
an interrupted aortic arch (type B) with truncus arter-
iosus, the same defect seen in the patient described by
Yamagishi et al. (1999). The report by Rauch et al. fur-
ther emphasizes the likelihood that the 22q11.2-related
cardiac defects are unlikely to result from defects in-
volving a single gene within the TDR.
We have identified a patient, CH98-18 (Emanuel et
al. 1998), with a novel deletion of chromosome 22q11.2.
His deletion is distal to the usual 3-Mb deletion found
in most patients with VCFS and appears to overlap with
a portion of the deleted region described by Rauch et
al. (1999). The deletion does not overlap with any
of the previously described “minimal critical regions”
for VCFS/DGS. The patient was born to a 33-year-old
mother at 35 wk gestation. The pregnancy was com-
plicated by a weight gain of 70 lbs and premature rup-
ture of membranes. The baby was delivered by cesarean
section, because of breech presentation, with Apgar
scores of 7 at 1 min and 8 at 5 min. Physical examination
at birth was notable for an appropriate-for-gestational-
age infant with hypertelorism, posteriorly rotated ears,
micrognathia, a loud cardiac murmur, hypospadias, de-
scended testes, single palmar creases, and 5th-finger cli-
nodactyly bilaterally. Renal and cranial ultrasounds
were normal. Echocardiography showed the presence of
truncus arteriosus type II and a ventricular septal defect.
Borderline hypocalcemia was also present. The patient
had surgical repair of his truncus arteriosus at age 3 wk
and a replacement graft at age 7 mo.
Motor development was normal. The patient sat at
age 6 mo and walked at age 14 mo. However, he had
expressive-speech delay, speaking his first words at age
21 mo. At age 26 mo, he had speech appropriate for an
18-month-old. During a recent physical examination at
age 26 mo (fig. 1), short stature, microcephaly, a prom-
inent glabella, partially attached earlobes, a broad nasal
bridge, a broad nasal tip with a crease, hypoplastic nasal
alae, anteverted nares, a featureless philtrum, a down-
turned mouth, a bifid uvula, and normal hearing and
vision were noted. Endocrine evaluation including thy-
roid-function and growth-hormone panels was unre-
markable. Immunologic studies including surface mark-
ers for T-cell, B-cell, and NK lineages, myeloid markers,
leukocyte adhesion, and Wiskott-Aldrich–associated
